Meta-correlation of the effect of ketamine and psilocybin induced subjective effects on therapeutic outcome.
Study Goal
The researchers aimed to determine the role of subjective effects and dissociation in mediating psilocybin-induced therapeutic outcomes for depression and substance use disorder (SUD).
Results Summary
The study found a greater mediating effect of subjective symptoms for psilocybin compared to ketamine, particularly in depression, with an R2-value of 24%. Psilocybin showed stronger therapeutic mediation in SUD than in depression.
Population
Patients with depression or substance use disorder (SUD).
Effective Dosage
Not available
Duration
Not available
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
ketamine | increase | therapeutic outcomes | patients with depression or SUD | R2-values ranging from 5-10% | modest role for subjective effects mediating therapeutic outcomes | #1 |
psilocybin | increase | therapeutic outcomes | patients with depression or SUD | R2 was 24% | greater mediating effect for subjective effects mediating therapeutic outcomes | #2 |
psilocybin | increase | therapeutic outcomes | patients with depression | - | greater mediating effect | #3 |
- | increase | therapeutic outcomes | patients with SUD | - | greater mediating effect | #4 |
There is some evidence that the subjective effects of ketamine and other psychedelics like psilocybin are crucial for their therapeutic outcomes, such as treatment of depression or substance use disorder (SUD). We performed a meta-analysis and systematic review on the correlation of subjective symptoms and dissociation versus ketamine-induced therapeutic outcomes in patients with depression or SUD. A similar analysis was conducted for psilocybin-induced therapeutic improvement. We retrieved 23 papers studying ketamine (21 on depression, 2 on SUD) in 471 patients and 8 papers studying psilocybin (6 on depression, 2 on SUD) in 183 patients. Our study demonstrated a modest role for subjective effects mediating therapeutic outcomes, with R2-values ranging from 5-10% for ketamine and for psilocybine the R2 was 24%. A greater mediating effect for psilocybin compared to ketamine was detected, particularly when restricting the analysis to depression. Additionally there is a greater mediating effect in SUD than depression, irrespective of treatment.